WeChat and live broadcasts: How Herbalife China is maintaining business amid COVID-19
Herbalife China has been using WeChat and live broadcasting to engage its customers amid the COVID-19 pandemic.
Direct-selling firms which traditionally rely on in-person interaction are one of the most affected industries, since face-to-face communication has been suspended.
For some, earlier efforts at digital transformation are now paying even greater results.
TCM and COVID-19: China conducting trials to test efficacy and safety of traditional herbal interventions
China is conducting clinical trials to assess the effectiveness and safety of combining traditional Chinese medicine (TCM) and conventional Western antiviral medicine in the treatment of patients with the novel coronavirus (COVID-19).
Yu Yanhong, deputy head of China's National Administration of Traditional Chinese Medicine under the National Health Commission, said more than 50,000 infected patients who received TCM treatment had recovered and were discharged.
In a recent briefing focusing on these TCM treatments, Yu said there were six TCM medicines and formulas involved, namely the herbal products jinhua qinggan granule, lianhua qingwen capsule, huashi baidu formula, and xuanfei baidu formula, along with xuebijing injection, lung cleansing and detoxifying decoction.
Trade war bruise: China to US health foods exports drop by over 11%
The trade war between China and US has left China bruised, with the export value of health foods and ingredients to the US down 11.7% last year.
This has caused China export to the US to drop to US$300m. Exports to the US now consist of 15.9% of China’s health food and ingredient exports.
The is according to the latest report by the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMPHIE).
H&H CEO interview: Baby nutrition boom, Swisse’s expansion surge and COVID-19 contingency planning revealed
The CEO of Health and Happiness (H&H) Group has revealed how its baby nutrition products are booming in China and further afield, underlined Swisse’s ambitious international expansion plans, but acknowledged there were some supply chain risks amid the COVID-19 pandemic.
Laetitia Garnier spoke to us after the firm saw its FY19 revenue increase by 7.8% to reach RMB10,925 million (USD 1,566 million), mostly led by its strong performance in its baby nutrition and care segment.
The company released its FY19 financial report on March 23, stating that the group managed to show continued growth despite the slowing global economy.
Export challenge: China’s botanical firms in supply chain battle as global orders rebound for immunity ingredients
The COVID-19 epidemic has led to a rebound in demand for plant extracts with immune-boosting effects, but a China industry expert has warned there are difficulties in exporting the goods due to logistic supply chain problems.
Shaanxi Plant Extract Association, which has over 100 member companies, said that although China had come to a market standstill due to the coronavirus outbreak, business started to pick up in early March.
According to Yinjun Hou, the chairman of the commerce department at the association, about 80% of its member companies have resumed work and the spread of the coronavirus in the US and Europe has increased the orders that it has received for its immune-boosting plant extracts.